In the case of Association for Molecular Pathology v. Myriad Genetics, Inc. the U.S. Supreme Court unanimously ruled that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA (“cDNA”) is patent eligible because it is not naturally occurring. The distinction is …
